Company intelligence / Profile preview

TOT BIOPHARM

Suzhou, Jiangsu Province, China3s-guojian.com ↗

Ownership: Private
Employees: ~572
Development stage: Commercial

Overview

TOT BIOPHARM is a leading Chinese biopharmaceutical company focused on innovative oncology drugs. It has achieved commercial production of its core product "Puxinting"® (bevacizumab biosimilar), with strong revenue growth in 2023. The company also provides one-stop CDMO services compliant with FDA/EMA/NMPA standards for biologics including monoclonal antibodies and ADCs[9][1][2]. Its pipeline includes multiple mAbs, ADCs, oncolytic viruses and specialty tumor drugs such as liposomal formulations.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody-drug conjugateOncolytic virus therapyLiposome-based drug (liposomal formulation)Small molecule
Industry: Biotech

Beyond the preview

Go deeper on TOT BIOPHARM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOT BIOPHARM.

Explore the full profile